Version 1
: Received: 13 August 2024 / Approved: 14 August 2024 / Online: 16 August 2024 (03:43:30 CEST)
How to cite:
FAIENZA, M. F.; Farella, I.; Khalil, M.; Portincasa, P. Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children. Preprints2024, 2024081112. https://doi.org/10.20944/preprints202408.1112.v1
FAIENZA, M. F.; Farella, I.; Khalil, M.; Portincasa, P. Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children. Preprints 2024, 2024081112. https://doi.org/10.20944/preprints202408.1112.v1
FAIENZA, M. F.; Farella, I.; Khalil, M.; Portincasa, P. Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children. Preprints2024, 2024081112. https://doi.org/10.20944/preprints202408.1112.v1
APA Style
FAIENZA, M. F., Farella, I., Khalil, M., & Portincasa, P. (2024). Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children. Preprints. https://doi.org/10.20944/preprints202408.1112.v1
Chicago/Turabian Style
FAIENZA, M. F., Mohamad Khalil and Piero Portincasa. 2024 "Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children" Preprints. https://doi.org/10.20944/preprints202408.1112.v1
Abstract
In the past thirty years, childhood obesity rates have risen significantly worldwide, affecting over 340 million children in affluent nations. This surge is intricately tied to metabolic disorders, notably insulin resistance, type 2 diabetes mellitus (T2DM), and the continually evolving spectrum of metabolic-associated (dysfunction) steatotic liver disease (MASLD). This review underscores the alarming escalation of childhood obesity and delves comprehensively into the evolving and dynamic changes of nomenclature surrounding diverse conditions of hepatic steatosis, from the initial recognition of non-alcoholic fatty liver disease (NAFLD) to the progressive evolution into MASLD. Moreover, it emphasizes the crucial role of pediatric endocrinologists in thoroughly and accurately investigating MASLD onset in children with T2DM where each condition influences and exacerbates the progression of the other. The review critically highlights the inadequacies of current screening strategies and diagnosis, stressing the need for a paradigm shift. A proposed solution involves the integration of hepatic magnetic resonance imaging assessment in the diagnostic arsenal for children showing insufficient glycaemic control and weight loss post-T2DM diagnosis, thereby complementing conventional liver enzyme testing. This holistic approach aims to significantly enhance diagnostic precision, fostering improved outcomes in this vulnerable high-risk pediatric population.
Medicine and Pharmacology, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
